ALLY Trial Demonstrates High Cure Rates for Investigational Daclatasvir and Sofosbuvir Combination among Genotype 3 Hepatitis C Patients Daclatasvir sofosbuvir regimen achieves SVR12 in 90% of treatment-naïve and 86% of - Peginterferon alfa-2b - Document - PDFSEARCH.IO

First Page	Meta Content
	ALLY Trial Demonstrates High Cure Rates for Investigational Daclatasvir and Sofosbuvir Combination among Genotype 3 Hepatitis C Patients Daclatasvir+sofosbuvir regimen achieves SVR12 in 90% of treatment-naïve and 86% of Add to Reading List Document Date: 2014-11-10 11:48:39 Open Document File Size: 101,71 KB Share Result on Facebook City PRINCETON / Boston / / Company Bristol-Myers Squibb Company / / Event FDA Phase / / Facility University of Florida / / MedicalCondition abdominal pain / insomnia / fatigue / HIV / disease / headache / arthralgia / complex disease / diarrhea / nausea / HCV / HCV RNA / / MedicalTreatment liver transplant / / Organization University of Florida / Microbiology Director / UF Clinical and Translational Science Institute / American Association for the Study of Liver Diseases / / Person David R. Nelson / Douglas Manion / / Position head / Assistant Vice President of Research / Professor of Medicine / / Product ribavirin / ALLY-3 / / ProvinceOrState New Jersey / Florida / Massachusetts / / Technology Genotype / / URL http / SocialTag Hepatitis C and HIV co-infection Ribavirin Biology Genetics Medicine MiR-122 Hepatitis Protease inhibitors Hepatitis C

ALLY Trial Demonstrates High Cure Rates for Investigational Daclatasvir and Sofosbuvir Combination among Genotype 3 Hepatitis C Patients Daclatasvir+sofosbuvir regimen achieves SVR12 in 90% of treatment-naïve and 86% ofAdd to Reading List